Open Access Highly Accessed Research article

Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis

Diego C Rossi1, Julian E Muñoz2, Danielle D Carvalho3, Rodrigo Belmonte1, Bluma Faintuch4, Primavera Borelli5, Antonio Miranda6, Carlos P Taborda2 and Sirlei Daffre1*

Author Affiliations

1 Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof Lineu Prestes, 1374, 05508-900 São Paulo, SP, Brazil

2 Department of Microbiology, Institute of Biomedical Sciences and Laboratory of Medical Mycology IMT/SP - LIM53, University of São Paulo, São Paulo, SP, Brazil

3 Department of Special Analysis, SD&W Modelagem e Soluções Estratégicas Ltda., São Paulo, SP, Brazil

4 Radiopharmacy Center, Institute of Energetic and Nuclear Research, São Paulo, Brazil

5 Department of Clinical and Toxicological Analyses, Faculty of Pharmaceutical Sciences, São Paulo University, São Paulo, SP, Brazil

6 Departament of Biophysics, University Federal of São Paulo, São Paulo, SP, Brazil

For all author emails, please log on.

BMC Microbiology 2012, 12:28  doi:10.1186/1471-2180-12-28

Published: 6 March 2012



Antimicrobial peptides are present in animals, plants and microorganisms and play a fundamental role in the innate immune response. Gomesin is a cationic antimicrobial peptide purified from haemocytes of the spider Acanthoscurria gomesiana. It has a broad-spectrum of activity against bacteria, fungi, protozoa and tumour cells. Candida albicans is a commensal yeast that is part of the human microbiota. However, in immunocompromised patients, this fungus may cause skin, mucosal or systemic infections. The typical treatment for this mycosis comprises three major categories of antifungal drugs: polyenes, azoles and echinocandins; however cases of resistance to these drugs are frequently reported. With the emergence of microorganisms that are resistant to conventional antibiotics, the development of alternative treatments for candidiasis is important. In this study, we evaluate the efficacy of gomesin treatment on disseminated and vaginal candidiasis as well as its toxicity and biodistribution.


Treatment with gomesin effectively reduced Candida albicans in the kidneys, spleen, liver and vagina of infected mice. The biodistribution of gomesin labelled with technetium-99 m showed that the peptide is captured in the kidneys, spleen and liver. Enhanced production of TNF-α, IFN-γ and IL-6 was detected in infected mice treated with gomesin, suggesting an immunomodulatory activity. Moreover, immunosuppressed and C. albicans-infected mice showed an increase in survival after treatment with gomesin and fluconazole. Systemic administration of gomesin was also not toxic to the mic


Gomesin proved to be effective against experimental Candida albicans infection. It can be used as an alternative therapy for candidiasis, either alone or in combination with fluconazole. Gomesin's mechanism is not fully understood, but we hypothesise that the peptide acts through the permeabilisation of the yeast membrane leading to death and/or releasing the yeast antigens that trigger the host immune response against infection. Therefore, data presented in this study reinforces the potential of gomesin as a therapeutic antifungal agent in both humans and animals.